

## 英文論文

### (原著+症例報告)

1. Nakahara T, Kido-Nakahara M, Ulzii D, Miake S, Fujishima K, Sakai S, Chiba T, Tsuji G, Furue M. Topical application of endothelin receptor antagonist attenuates imiquimod-induced psoriasiform skin inflammation. *Sci Rep.* 2020 Jun 11;10(1):9510.
2. Nakahara T, Izuhara K, Onozuka D, Nunomura S, Tamagawa-Mineoka R, Masuda K, Ichiyama S, Saeki H, Kabata Y, Abe R, Ohtsuki M, Kamiya K, Okano T, Miyagaki T, Ishiujii Y, Asahina A, Kawasaki H, Tanese K, Mitsui H, Kawamura T, Takeichi T, Akiyama M, Nishida E, Morita A, Tonomura K, Nakagawa Y, Sugawara K, Tateishi C, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Hide M, Aoki N, Sano S, Matsuda-Hirose H, Hatano Y, Takenaka M, Murota H, Katoh N, Furue M. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol. *Medicine (Baltimore).* 2020 Sep 18;99(38):e22043.
3. imiquimod-induced psoriasiform skin inflammation. *Sci Rep.* 2020 Jun 11;10(1):9510.
4. Kido-Nakahara M, Nakahara T, Yasukochi Y, Ulzii D, Furue M. Patient-Oriented Eczema Measure score: A Useful Tool for Web-Based Surveys in Patients with Atopic Dermatitis. *Acta Derm Venereol.* 2020 May 28;100(10):adv00159.
5. Kido-Nakahara M, Wang B, Ohno F, Tsuji G, Ulzii D, Takemura M, Furue M, Nakahara T. Inhibition of mite-induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan. *Allergy.* 2020 Jun 14. doi: 10.1111/all.14451. Epub ahead of print. PMID: 32535962.
6. Tsuji G, Hashimoto-Hachiya A, Yen VH, Takemura M, Yumine A, Furue K, Furue M, Nakahara T. Metformin inhibits IL-1 $\beta$  secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis. *Cell Death Discov.* 2020 Mar 4;6:11. doi: 10.1038/s41420-020-0245-8. PMID: 32194991; PMCID: PMC7055596.
7. Tsuji G, Hashimoto-Hachiya A, Yen VH, Miake S, Takemura M, Mitamura Y, Ito T, Murata M, Furue M, Nakahara T. Aryl Hydrocarbon Receptor Activation Downregulates IL-33 Expression in Keratinocytes via Ovo-Like 1. *J Clin Med.* 2020 Mar 24;9(3):891. doi: 10.3390/jcm9030891. PMID: 32214018; PMCID: PMC7141508.
8. Itoh E, Furumura M, Furue M. Rate of actual metal allergy prior to dental treatment in subjects complaining of possible metal allergy. *Asian Pac J Allergy Immunol.* 2020 Sep;38(3):186-189.
9. Kurihara Y, Koji Kawamura, Furue M. A case of epidermal cyst with underlying lipoma on the back: rare presentation. *Case Rep Dermatol.* DOI 513474.
10. Chiba T, Nagai T, Kohda F, Nakahara T, Kono M. The Connection between Urinary

Equal Levels and the Prevalence of Atopic Dermatitis. *Int Arch Allergy Immunol.* 2020 Sep 15;1-7.

11. Ito T, Kaku-Ito Y, Wada-Ohno M, Furue M. Narrow-Margin Excision for Invasive Acral Melanoma: Is It Acceptable? *J Clin Med.* 2020 Jul 16;9(7):2266.
12. Ito T, Kaku-Ito Y, Murata M, Furue K, Shen CH, Oda Y, Furue M. Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival. *J Clin Med.* 2020 Mar 4;9(3):690.
13. Murata M, Ito T, Tanaka Y, Kaku-Ito Y, Furue M. NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target. *Int J Mol Sci.* 2020 Aug 16;21(16):5891.
14. Murata M, Ito T, Tanaka Y, Yamamura K, Furue K, Furue M. OVOL2-Mediated ZEB1 Downregulation May Prevent Promotion of Actinic Keratosis to Cutaneous Squamous Cell Carcinoma. *J Clin Med.* 2020 Feb 25;9(3):618.
15. Jinnai S, Yamazaki N, Hirano Y, Sugawara Y, Ohe Y, Hamamoto R. The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning. *Biomolecules* 2020 Oct 1123.
16. Ichiki T, Sugita K, Furue M, Yamamoto O. An Intimate Relationship Between Intralesional Depigmentation and Peripheral Nervous System in Lichen Simplex Chronicus. *Acta Derm Venereol.* 2020 Jan 30;100(1):adv00042.
17. Eto A, Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Acrosyringeal endothelin-1 expression: Potential for fostering melanocytes in volar sites. *J Dermatol.* 2020 Aug;47(8):924-925.
18. Eto A, Nakahara T, Furue M. Repeated infliximab injection may shift delayed infusion reactions to acute infusion reactions in patients with psoriasis. *J Dermatol.* 2020 Oct 18. doi: 10.1111/1346-8138.15652. Epub ahead of print. PMID: 33073412.
19. Koito R, Kohda F, Dugu L, Suenaga A, Ichiki T, Furue M. Scrotal angiomyxoma. *Australas J Dermatol.* 2020 Feb;61(1):78-79.
20. Sato S, Chiba T, Nakahara T, Furue M. Upregulation of IL-36 cytokines in folliculitis and eosinophilic pustular folliculitis. *Australas J Dermatol.* 2020 Feb;61(1):e39-e45.
21. Sato S, Nakahara M, Kato K, Moriyama T, Utsumi S, Sasaki K, Shima T, Miyoshi H, Yamamoto H, Furue M. Plasmablastic lymphoma occurring in the vicinity of enterocutaneous fistula in Crohn's disease. *J Dermatol.* 2020 Dec;47(12):e442-e443.
22. Furue K, Ito T, Tanaka Y, Hashimoto-Hachiya A, Takemura M, Murata M, Kido-Nakahara M, Tsuji G, Nakahara T, Furue M. The EGFR-ERK/JNK-CCL20 Pathway in

- Scratched Keratinocytes May Underpin Koebnerization in Psoriasis Patients. *Int J Mol Sci.* 2020 Jan 9;21(2):434.
23. Furue K, Ito T, Tsuji G, Nakahara T, Furue M. Scratch wound-induced CXCL8 upregulation is EGFR-dependent in keratinocytes. *J Dermatol Sci.* 2020 Sep;99(3):209–212.
  24. Satake M, Kudo K, Masuda A, Onoyama S, Furuno K, Furue M. Drug-induced hypersensitivity syndrome by i.v. immunoglobulin administration for Kawasaki disease. *J Dermatol.* 2020 Mar;47(3):e74–e75.
  25. Hashimoto H, Ito T, Yamada Y, Oda Y, Furue M. Eosinophilic infiltration discriminates lichen-planus-like eruption caused by an immune checkpoint inhibitor from ordinary lichen planus. *J Dermatol.* 2020 Nov 21. doi: 10.1111/1346-8138.15705. Epub ahead of print. PMID: 33219712.
  26. Hashimoto H, Ito T, Ide T, Sasaki N, Hikichi S, Furue M. Pyrexia by COVID-19 in a patient treated with dabrafenib/trametinib therapy. *J Dermatol.* 2020 Nov 16. doi: 10.1111/1346-8138.15696. Epub ahead of print. PMID: 33200424.
  27. Hashimoto H, Kageyama T, Sakai H, Tsukuura R. Vascularized genitofemoral nerve flap based on the deep branch of the superficial circumflex iliac artery. *J Reconstr Microsurg* 2020; 36: e1–e2.
  28. Tanaka Y, Ito T, Tsuji G, Furue M. Baicalein Inhibits Benzo[a]pyrene-Induced Toxic Response by Downregulating Src Phosphorylation and by Upregulating NRF2-HMOX1 System. *Antioxidants (Basel).* 2020 Jun 9;9(6):507.
  29. Yumine A, Tsuji G, Furue M. Selective PPAR $\alpha$  agonist pemafibrate inhibits TNF- $\alpha$ -induced S100A7 upregulation in keratinocytes. *J Dermatol Sci.* 2020 Jul;99(1):69–72.
  30. Vu YH, Hashimoto-Hachiya A, Takemura M, Yumine A, Mitamura Y, Nakahara T, Furue M, Tsuji G. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis. *Int J Mol Sci.* 2020 Dec 10;21(24):E9412. doi: 10.3390/ijms21249412.
  31. Tsutsui K, Namikawa K, Mori T, Kato K, Jinnai S, Nakama K, Ogata D, Takahashi A, Yamazaki N. Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. *J Dermatol.* 2020 Dec 2. doi: 10.1111/1346-8138.15718.
  32. Takahashi A, Namikawa K, Ogata D, Nakano E, Jinnai S, Nakama K, Tsutsui K, Muto Y, Mizuta H, Yamazaki N. Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. *J. Dermatol.* 2020 47: 1267–1275.

33. Hamamoto R, Suvarna K, Yamada M, Kobayashi K, Shinkai N, Miyake M, Takahashi M, Jinnai S, Shimoyama R, Sakai A, Takasawa K, Bolatkan A, Shozu K, Dozen A, Machino H, Takahashi S, Asada K, Komatsu M, Sese J, Kaneko S. Application of Artificial Intelligence Technology in Oncology: Towards the Establishment of Precision Medicine. *Cancers* 2020, 12(12), 3532.
34. Tsutsui K, Namikawa K, Mori T, Jinnai S, Nakama K, Ogata D, Takahashi A, Yamazaki N. Case of multiple ectopic extramammary Paget's disease of the trunk. *J Dermatol.* 47: e329–e331.
35. Nakano E, Takahashi A, Namikawa K, Muto Y, Jinnai S, Kage Y, Mizuta H, Tsutsumida A, Yamazaki N. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study. *J Dermatol.* 47: 622–628.
36. Tsutsui K, Takahashi A, Muto Y, Mizuta H, Jinnai S, Nakama K, Ogata D, Namikawa K, Yamazaki N. Outcomes of lymph node dissection in the treatment of extramammary Paget's disease: A single-institution study. *J Dermatol.* 2020, 47: 512–517.
37. Yoshimoto M, Yamada Y, Ishihara S, Kohashi K, Toda Y, Ito Y, Yamamoto H, Furue M, Nakashima Y, Oda Y. Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review. *Am J Surg Pathol.* 2020 Jan;44(1):87–97.
38. Kaneko S, Tsuruta N, Yamaguchi K, Miyagi T, Takahashi K, Higashi Y, Morizane S, Nomura H, Yamaguchi M, Hino R, Sawada Y, Nakamura M, Ohyama B, Ohata C, Yonekura K, Hayashi H, Yanase T, Matsuzaka Y, Sugita K, Kikuchi S, Mitoma C, Nakahara T, Furue M, Okazaki F, Koike Y, Imafuku S; Western Japan Inflammatory Disease Research Group. Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: Real-world data from 18 Japanese facilities. *J Dermatol.* 2020 Feb;47(2):128–132.
39. Fujimura T, Yoshino K, Kato H, Fujisawa Y, Nakamura Y, Yamamoto Y, Kurimoto K, Ito T, Matsushita S, Maekawa T, Ohuchi K, Amagai R, Muto Y, Kambayashi Y, Hashimoto A, Aiba S. Case series of BRAF mutated advanced melanoma treated with encorafenib plus binimetinib combined therapy. *J Dermatol*, in press
40. Egashira N, Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, Masuda S, Okamoto I, Nakagawa T, Ito T, Eto M, Mori M, Nakanishi Y. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. *Scientific Rep*, in press

41. Kamio Y, Gunge Y, Koike Y, Kuwatsuka Y, Tsuruta K, Yanagihara K, Furue M, Murota H. Insight into innate immune response in "Yusho": The impact of natural killer cell and regulatory T cell on inflammatory prone diathesis of Yusho patients. *Environ Res.* 2020 Jun;185:109415.
42. Kinoshita I, Yamada Y, Kohashi K, Yamamoto H, Iwasaki T, Ishihara S, Toda YU, Ito Y, Susuki Y, Kawaguchi K, Ichiki T, Sato Y, Furue M, Nakashima Y, Oda Y. Frequent MN1 Gene Mutations in Malignant Peripheral Nerve Sheath Tumor. *Anticancer Res.* 2020 Nov;40(11):6221–6228.
43. Sagata N, Kano SI, Ohgidani M, Inamine S, Sakai Y, Kato H, Masuda K, Nakahara T, Nakahara–Kido M, Ohga S, Furue M, Sawa A, Kanba S, Kato TA. Forskolin rapidly enhances neuron–like morphological change of directly induced–neuronal cells from neurofibromatosis type 1 patients. *Neuropsychopharmacol Rep.* 2020 Dec;40(4):396–400.
44. Asahina R, Ueda K, Oshima Y, Kanei T, Kato M, Furue M, Tsukui T, Nagata M, Maeda S. Serum canine thymus and activation–regulated chemokine (TARC/CCL17) concentrations correlate with disease severity and therapeutic responses in dogs with atopic dermatitis. *Vet Dermatol.* 2020 Dec;31(6):446–455.
45. Onozuka D, Nakamura Y, Tsuji G, Furue M. Mortality in Yusho patients exposed to polychlorinated biphenyls and polychlorinated dibenzofurans: a 50–year retrospective cohort study. *Environ Health.* 2020 Nov 23;19(1):119.
46. Arakawa H, Shimojo N, Katoh N, Hiraba K, Kawada Y, Yamanaka K, Igawa K, Murota H, Okafuji I, Fukuie T, Nakahara T, Noguchi T, Kanakubo A, Katayama I. Consensus statements on pediatric atopic dermatitis from dermatology and pediatrics practitioners in Japan: Goals of treatment and topical therapy. *Allergol Int.* 2020 Jan;69(1):84–90.
47. Takechi T, Hirota T, Fujii K, Nakahara T, Sakai T, Maeda N, Furue M, Ieiri I. Effect of Genetic Polymorphisms of Human SLC22A3 in the 5'–flanking Region on OCT3 Expression and Sebum Levels in Human Skin. *J Dermatol Sci.* 2020 Oct 24:S0923–1811(20)30328–5. doi: 10.1016/j.jdermsci.2020.10.010. Epub ahead of print. PMID: 33168399.
48. Yamasaki R, Yonekawa T, Inamizu S, Shinoda K, Ochi H, Matsushita T, Isobe N, Tsuji G, Sadashima S, Kuma Y, Oda Y, Iwaki T, Furue M, Kira JI. A case of overlapping adult–onset linear scleroderma and Parry–Romberg syndrome presenting with widespread ipsilateral neurogenic involvement. *Neuropathology.* 2020 Feb;40(1):109–115.
49. Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, Williams HC, Schmitt J, Gabes M, Howells L, Stuart BL, Grinich E, Pawlitschek T, Burton T, Howie L, Gadkari A, Eckert L, Ebata T, Boers M, Saeki H, Nakahara T, Katoh N.

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. *Br J Dermatol.* 2020 Nov 11. doi: 10.1111/bjd.19673.

50. Sagata N, Kano SI, Ohgidani M, Inamine S, Sakai Y, Kato H, Masuda K, Nakahara T, Nakahara-Kido M, Ohga S, Furue M, Sawa A, Kanba S, Kato TA. Forskolin rapidly enhances neuron-like morphological change of directly induced-neuronal cells from neurofibromatosis type 1 patients. *Neuropsychopharmacol Rep.* 2020 Dec;40(4):396-400.
51. Ishida Y, Kakiuchi N, Yoshida K, Inoue Y, Irie H, Kataoka TR, Hirata M, Funakoshi T, Matsushita S, Hata H, Uchi H, Yamamoto Y, Fujisawa Y, Fujimura T, Saiki R, Takeuchi K, Shiraishi Y, Chiba K, Tanaka H, Otsuka A, Miyano S, Kabashima K, Ogawa S. Unbiased Detection of Driver Mutations in Extramammary Paget Disease. *Clin Cancer Res.* 2020 Dec 15;clincanres.3205.2020. doi: 10.1158/1078-0432.CCR-20-3205.
52. Ishii M, Hirai I, Tanese K, Fusumae T, Nakamura Y, Fukuda K, Uchi H, Kabashima K, Otsuka A, Yokota K, Yamazaki N, Namikawa K, Fujimura T, Takenouchi T, Yamamoto Y, Nishiguchi M, Sato Y, Amagai M, Funakoshi T. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study). *Medicine (Baltimore).* 2020 Oct 30;99(44):e22913.
53. Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, Takatsuka S, Koga H, Wada N, Minami H, Hatsumichi M, Namba Y, Yamazaki N. Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naïve advanced melanoma. *J Dermatol.* 2020 Nov;47(11):1257-1266.
54. Nakamura Y, Namikawa K, Yoshino K, Yoshikawa S, Uchi H, Goto K, Nakamura Y, Fukushima S, Kiniwa Y, Takenouchi T, Uhara H, Kawai T, Hatta N, Funakoshi T, Teramoto Y, Otsuka A, Doi H, Ogata D, Matsushita S, Isei T, Hayashi T, Shibayama Y, Yamazaki N. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. *Ann Oncol.* 2020 Sep;31(9):1198-1206.
55. Fujisawa Y, Fujimura T, Matsushita S, Yamamoto Y, Uchi H, Otsuka A, Funakoshi T, Miyagi T, Hata H, Gosho M, Kambayashi Y, Aoki M, Yanagi T, Ohira A, Nakamura Y, Maeda T, Yoshino K. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study. *Br J Dermatol.* 2020 Nov;183(5):831-839.
56. Matsubara T, Uchi H, Haratake N, Takamori S, Toyozawa R, Miura N, Yamaguchi M, Seto T, Takenoyama M. Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma. *Clin Lung Cancer.* 2020 Mar;21(2):e54-e56.

57. Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, Takatsuka S, Koga H, Wada N, Minami H, Hatsumichi M, Namba Y, Yamazaki N. Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naïve advanced melanoma. *J Dermatol.* 2020 Nov;47(11):1257–1266. doi: 10.1111/1346-8138.15514. Epub 2020 Aug 18.
58. Mochizuki T, Tsuboi R, Iozumi K, Ishizaki S, Ushigami T, Ogawa Y, Kaneko T, Kawai M, Kitami Y, Kusuhara M, Kono T, Sato T, Sato T, Shimoyama H, Takenaka M, Tanabe H, Tsuji G, Tsunemi Y, Hata Y, Harada K, Fukuda T, Matsuda T, Maruyama R; Guidelines Committee of the Japanese Dermatological Association. Guidelines for the management of dermatomycosis (2019). *J Dermatol.* 2020 Dec;47(12):1343–1373. doi: 10.1111/1346-8138.15618. Epub 2020 Sep 25. PMID: 32978814.
59. Leshem YA, Chalmers JR, Apfelbacher C, Furue M, Gerbens LAA, Prinsen CAC, Schmitt J, Spuls PI, Thomas KS, Williams HC, Simpson EL; Harmonising Outcome Measures for Eczema (HOME) initiative. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. *J Am Acad Dermatol.* 2020 May;82(5):1181–1186.

#### (総説)

1. Furue M, Ulzii D, Nakahara T, Tsuji G, Furue K, Hashimoto-Hachiya A, Kido-Nakahara M. Implications of IL-13R  $\alpha$  2 in atopic skin inflammation. *Allergol. Int.* 2020, 69, 412–416.
2. Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and Keratinocytes in Psoriasis. *Int J Mol Sci.* 2020 Feb 13;21(4):1275.
3. Furue M. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. *Int J Mol Sci.* 2020 Jul 29;21(15):5382.
4. Furue M, Nakahara T. Revival of AHR agonist for the treatment of atopic dermatitis: tapinarof. 2020, *Curr Treat Options Allergy* 2020; 7: 414–421.
5. Furue M. Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4–JAK–STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis. *J Clin Med.* 2020 Nov 20;9(11):3741.
6. Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. *J Dermatol.* 2020 Oct 29. doi: 10.1111/1346-8138.15664. Epub ahead of print. PMID: 33118662.
7. Ito T, Tanaka Y, Murata M, Kaku-Ito Y, Furue K, Furue M. Genetic heterogeneity of melanoma. *Curr Treat Option Oncol*, in press

8. Mitamura Y, Nunomura S, Furue M, Izuhara K. IL-24: A new player in the pathogenesis of pro-inflammatory and allergic skin diseases. *Allergol Int.* 2020, 69, 405-411.
9. Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, Shimojo N, Tanaka A, Nakahara T, Nagao M, Hide M, Fujita Y, Fujisawa T, Futamura M, Masuda K, Murota H, Yamamoto-Hanada K. Japanese guidelines for atopic dermatitis 2020. *Allergol Int.* 2020 Jul;69(3):356-369.
10. Furue K, Ulzii D, Tanaka Y, Ito T, Tsuji G, Kido-Nakahara M, Nakahara T, Furue M. Pathogenic implication of epidermal scratch injury in psoriasis and atopic dermatitis. *J Dermatol.* 2020 Sep;47(9):979-988.
11. Furue K, Ito T, Tsuji G, Nakahara T, Furue M. The CCL20 and CCR6 axis in psoriasis. *Scand J Immunol.* 2020 Mar;91(3):e12846.

## 邦文

### (原著+症例報告)

1. 内 博史. 術後補助療法の実際. *Monthly Book Derma* 2020;298:62-68.
2. 内 博史. 鼻瘤の効果的な治療について. *皮膚科の臨床* 2020;62:852-854.
3. 工藤 恭子, 岡田 純一郎, 佐竹 真緒, 楠田 剛, 古江 増隆. Noonan syndrome-like disorder with loose anagen hair の1例. *西日本皮膚科* 82(1): 28-31, 2020
4. 吉田舞子, 江藤綾佳, 中原剛士, 古江増隆 上腕に生じた特異な外観を呈したグロムス腫瘍 末梢神経線維束の分布と痛みの関連について *西日本皮膚科* (0386-9784)82 巻3号 Page179-182, 2020
5. 中村美沙、古江増隆 最近話題の皮膚疾患 Dermatoporosis(皮膚粗鬆症) *臨床皮膚科* 74(5):10-15,2020
6. 栗原 雄一、塩道 泰子、太田 昌成、谷口 義章、古江 増隆 Streptococcus agalactiae による化膿性胸鎖関節炎の1例 *皮膚臨床* 62(8):1252-1253, 2020
7. 村田真帆、増野年彦、古江増隆、手指の壊死を生じたスチール症候群. *Visual Dermatology* 2020;19(9):924-926.
8. 北川徳子, 辻学, 中原真希子, 中原剛士, 古江増隆 Lipedematous Scalp(図説) *西日本皮膚科* (0386-9784)82 巻5号 Page331-332, 2020
9. 谷口 知与, 辻学, 竹井 賢二郎, 高原 正和, 安澤 数史, 松田 哲男, 古江 増隆, 外科的切除を行った *Fonsecaea monophora* による黒色分芽菌症の1例, *西日本皮膚科* 82(4):289-293,2020
10. 挽地史織、森澤紘美、高松紘子、原田佳代、占部和敬. Hereditary papulotranslucent acrokeratoderma (HPA). *皮膚病診療* 42, 666-669, 2020

11. 佐藤友紀、中原真希子、河原紗穂、大野麻衣子、中原剛士、内博史、古江増隆：  
右側前額部帯状疱疹後に生じた Wolf's isotopic response の 1 例、西日本皮膚科  
in press
12. 佐藤友紀、菊池智子、大野麻衣子、原口祐子、古賀恒久、古江増隆：急性腭炎を合併し  
た結節性多発動脈炎、皮膚病診療;vol42(6):520-523,2020
13. 佐藤清象, 中原真希子, 北川徳子, 與語晶子, 井手豪俊, 大野麻衣子, 吉田舞子, 辻  
学, 中原剛士, 古江増隆 西日本皮膚科 (0386-9784)82 卷 1 号 Page23-27, 2020
14. 佐藤清象, 中原真希子, 内博史, 宮崎玲子, 辻学, 中原剛士, 三苦千景, 古江増隆  
皮膚生検にて平滑筋肉腫が疑われた Atypical Fibroxanthoma の 1 例 西日本皮膚科  
(0386-9784)81 卷 6 号 Page487-490, 2019
15. 横手銀珠、古賀哲也、古江増隆. Granular Cell Tumor(GCT)の 2 例-Conventional GCT  
と Non-neutal GCT-. 西日本皮膚科 82(5):429-432,2020
16. 呉竹景介、小田真理、竹内聡、古江増隆. 口囲の MRSA 蜂窩織炎から生じた敗血症性  
肺塞栓症の一例 西日本皮膚科 82(4) 280-284, 2020.
17. 古江和久, 古江増隆. アトピー性皮膚炎における IL-17 産生細胞浸潤の新しい視点: *In  
vitro* 表皮細胞搔破モデルによる表皮細胞由来 CCL20 の役割. 日本皮膚科学会雑誌.  
130 卷 7 号 p1645-1652, 2020.
18. 藤井晴香、井手豪俊、佐々木諒、大野麻衣子、伊東孝通、古江増隆. 脂腺癌一Muir-  
Torre 症候群一. 皮膚病診療、42 卷 11 号 p992-994 2020.
19. 橋本弘規, 江藤綾桂, 永江航之介, 仲本すみれ, 佐藤友紀, 大野文嵩, 大野麻衣子,  
伊東孝通, 古江増隆. 頭部巨大基底細胞癌の 1 例. 西日本皮膚科 82: 433-437, 2020.
20. 加藤美和、江藤綾佳、松永拓磨、井上慶一、橋本弘規、水野亜美、芥菜実、平野早希  
子、古江和久、古江増隆、脂腺母斑における Endothelin-1 の発現様式;基底細胞癌の  
発生母地としての毛嚢分化を示す Endothelin-1 陽性表皮細胞群の可能性 西日本皮膚  
科 82(5):370-376,2020
21. 衛藤愛, 小田真理, 竹内聡、前川真貴子, 吉澤誠司、古江増隆. 限局性強皮症との鑑  
別を要した Morpheaform Sarcoidosis の 1 例 西日本皮膚科 2020 accepted for  
publication.
22. 杉町圭史, 井口友宏, 三浦奈央子, 河野美穂子, 和田尚子, 内博史, 陣内三佳子, 森田  
勝, 藤也寸志. 治療の実際 知っておきたいがん患者の緊急性・併存症. 臨床と研究  
(0021-4965) 97 卷 9 号 Page1179-1188(2020.9)
23. Hamano S, Nishima D, Satake M, Kudo K, Yanagita K, Tezuka J. Recurrent Immediate  
Type Hypersensitivity Reaction Induced by Macrogol in a 3-Year-Old Boy. J Investig  
Allergol Clin Immunol. 2020; 30(1): 72-73.

(総説)

1. 中原剛士 アレルギー相談室 Q&A 皮膚科 石鹼を含む洗浄剤の使用はアトピー性皮膚炎の管理に有用か? アレルギーの臨床 (0285-6379)40 巻 11 号 Page894, 2020
2. 中原剛士 皮膚そう痒症はなぜ下腿に多いのか? 皮膚科の臨床 61 巻 6 号 Page787-792, 2019 日本医事新報 (0385-9215)5026 号 Page48-49, 2020
3. 中原剛士 【アトピー性皮膚炎の診療ガイドライン】アトピー性皮膚炎のスキンケア アレルギーの臨床 (0285-6379)40 巻 6 号 Page443-446, 2020
4. 中原剛士 蕁麻疹の病態・診断・治療 アップデート 蕁麻疹診療ガイドラインの改定のポイント アレルギーの臨床 (0285-6379)40 巻 3 号 Page170, 2020
5. 中原剛士 アトピー性皮膚炎 update アトピー性皮膚炎に対するデュピルマブによる治療の実際 アレルギーの臨床 (0285-6379)42 巻 1 号 Page28-31, 2021
6. 中原剛士 【ゲノム医療と分子標的治療の最新情報】分子標的治療の実際(がん以外) 乾癬・アトピー性皮膚炎に対する生物学的製剤 臨床と研究 (0021-4965)97 巻 4 号 Page449-454, 2020
7. 中原剛士 【検査値を読む 2020】(18 章)アレルギー検査 TARC(Th2 ケモカイン) 内科 (0022-1961)125 巻 4 号 Page828, 2020
8. 中原剛士 【“顔の赤み”鑑別・治療アトラス】アトピー性皮膚炎 炎症による顔の赤み Derma. (1343-0831)294 号 Page27-32, 2020
9. 中原剛士 リレーエッセイ 私のワークバランス ワークライフバランスについて考えてみる 皮膚病診療
10. 中原 真希子 治療の実際 内科で診られる皮膚疾患 湿疹と誤診しやすい疾患と DPP-4 阻害薬による水疱症 臨床と研究 97 巻 10 号 p1311-1316, 2020/10.
11. 古江和久, 古江増隆. 乾癬に特有な Köbner 現象の病態に迫るー表皮細胞由来 CCL20 の重要性とその展望ー. 皮膚病診療. 42 巻 9 号 p740-745, 2020.

## (著書)

1. 中原剛士 蕁麻疹 ケースから学ぶコツとピットフォール オマリズマブの著効例 皮膚疾患 全身療法薬 Up-to-date, Page155-156, 2020
2. 伊東孝通 隆起性皮膚線維肉腫 今日の皮膚疾患治療指針 第 5 版 医学書院
3. 伊東孝通 未分化多形肉腫/悪性線維性組織球腫 今日の皮膚疾患治療指針 第 5 版 医学書院
4. 陣内駿一、山崎直也 医学のあゆみ 274 巻 9 号 【AI が切り拓く未来の医療】AI 技術の実臨床への応用 人工知能を用いた皮膚腫瘍予測システムの開発 2020/8
5. 古江和久, 古江増隆. 抗 IL-31RA モノクローナル抗体 ネモリズマブ. 皮膚疾患全身療法薬 Up-to-date. p33, 2020.

6. 林稔展、中原剛士 手足症候群 フローチャート 抗がん薬副作用 p137-147
7. 林稔展、中原剛士 皮膚障害(ざ瘡様皮疹、爪囲炎) フローチャート 抗がん薬副作用  
p148-161

**(雑文)**

1. 伊東孝通 九州大学皮膚科 医局紹介 福岡県医報
2. 伊東孝通 The second country, Taiwan 鳥取大学皮膚科同門会雑誌